FindTrial
Sign In

Adjuvant chemotherapy in stage III colon carcinoma in patients age or 70 years. Feasibility of CAPOX scheme oxaliplatin 70 mg/mq days 1-8 and capecitabine 1000 mg/mq X 2 die days 1-14 every 21 days for 6 cycles - ND

Adjuvant chemotherapy in stage III colon carcinoma in patients age or 70 years. Feasibility of CAPOX scheme oxaliplatin 70 mg/mq days 1-8 and capecitabine 1000 mg/mq X 2 die days 1-14 every 21 days for 6 cycles - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-000267-29-IT
Enrollment
15
Registered
2006-04-21
Start date
2006-01-01
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon carcinoma MedDRA version: 6.1 Level: PT Classification code 10061045

Interventions

Trade Name: ELOXATIN IV 1 FL 100 MG Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Oxaliplatin CAS Number: 61825-94-3 Concentration unit: mg milligram(s) Concentration type: equal Conc

Sponsors

Centro sociale oncologico
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Radically operated Stage III colon carcinoma . Age or 70 years. PS 0 or 1. Absence of preexisting peripheral neuropathy. Adequate liver and kidney functionality. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Metastatic colon carcinoma . PS 1. Creatinin clearance 30 . Blood bilirubin 1,5 times the normal level. Neuropaty of any degree and origin.

Design outcomes

Primary

MeasureTime frame
Main Objective: Valuation of dose intensity. Valuation of kind and seriousness of the side effects.;Secondary Objective: Valuation of desease free survival.;Primary end point(s): Valuation of dose intensity. Valuation of kind and seriousness of the side effects.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026